GlassScriptPhysician profile
Robert A Rosenzweig
NPI 1073508818
$1,414.83
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $273 · 2021: $385 · 2022: $655.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.14 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.07 | 2020-2022 | |
| Celgene Corporation | $133.82 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $118.86 | 2021-2022 | |
| Gilead Sciences, INC. | $102.75 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.24 | 2022 | |
| Qol Medical, LLC | $29.36 | 2019 | |
| Allergan, INC. | $19.98 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.67 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rosenzweig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.